Table 1 Characteristics of the 751 patients who entered the operating room
Sex Ratio (M/F) | 1.05 (384/367) |
|---|---|
Median Age (range) | 67 (25–86) |
Mean BMI (±SD) | 24.7 (±4.35) |
Period (%) | |
1 (February 2000–March 2011) | 224 (30) |
2 (April 2011–August 2019) | 527 (70) |
Biliary Stenting (%) | 418 (58%) |
Work up Imaging (%) | |
CT-scan | 751 (100) |
Liver Magnetic Resonance Imaging | 407 (54) |
Positron Emission Tomography | 69 (9) |
Median delay CT-Surgery (days) (range) | 18 (1–55) |
Mean CA 19–9 serum level* (UI) (±SD) (after jaundice resolution) | 552 (±1200) |
Neoadjuvant Treatment (%) | 337 (45) |
Explorative Laparoscopy (%) | 82 (11) |
Type of Surgery (%) | |
Exploration without Resection | 184 (25) |
Pancreaticoduodenectomy | 384 (51) |
Distal Pancreatectomy | 146 (19) |
Total Pancreatectomy | 37 (5) |
Venous Resection | 159 (21) |
Arterial Resection | 19 (2.4) |
En-bloc Resection of Neighbours Organs | 43 (5.7) |
Reason of Non-resection (%) | |
Carcinomatosis | 35 (5) |
Liver Metastasis | 49 (7) |
Vascular Invasion | 75 (10) |
Distant Lymph Node Invasion | 25 (3) |
Mean Size of Extra Pancreatic Metastasis (mm) (±SD) | 7.5 (±4.6) |
Morbidity (%) | |
Resected patients (Overall / Grades 3 to 5 Clavien-Dindo) | 279 (49) / 85 (15) |
Hemorrhage | 47 (8) |
Clinically Revelant Postoperative Pancreatic Fistula | 108 (219 |
Reintervention | 43 (8) |
Non-resected patients (Overall / Grades 3 to 5 Clavien-Dindo) | 33 (1.8) / 6 (3.2) |
30- / 90-days Mortality (%) | |
Resected patients | 24 (4.2) / 30 (5.3) |
Non-resected patients | 4 (2.2) / 10 (5.4) |
Pathologic Findings (Resected patients) | |
T1/2 (%) | 205 (36) |
T3/4 (%) | 362 (64) |
Median Number of Lymph Nodes (range) | 13 (2–44) |
N+ (%) | 329 (58) |
R1 (%) | 258 (46) |
Perineural Invasion (%) | 385 (68) |
Adjuvant Treatment (%)(Resected patients) | 352 (62) |